Galcanezumab API (CAS No. 1578199-75-3) is a recombinant humanized IgG4 monoclonal antibody associated with calcitonin gene-related peptide (CGRP)-targeted neurological biologic products.
Galcanezumab specifically binds to the CGRP ligand and blocks its interaction with the CGRP receptor. CGRP is involved in neurological signaling pathways associated with migraine and trigeminal pain mechanisms. By targeting the CGRP ligand, Galcanezumab inhibits CGRP-mediated biological activity.
Galcanezumab is produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells and has an approximate molecular weight of 147 kDa.
Pharmaceutical and biotechnology companies sourcing Galcanezumab biological active substance commonly evaluate protein identity, monoclonal antibody purity, biological potency, target-binding activity, aggregates, charge variants, glycosylation profile, host cell proteins, residual host cell DNA, endotoxin, bioburden, and process-related impurities.
Because Galcanezumab is a recombinant monoclonal antibody, batch-to-batch consistency in protein structure, CGRP-binding activity, aggregation profile, charge heterogeneity, and glycan characteristics is important during biologic and biosimilar development.
Swapnroop Drugs and Pharmaceuticals supplies Galcanezumab biological active material for qualified pharmaceutical research, biotechnology, monoclonal antibody development, analytical, and biologics development requirements with product-specific quality documentation and controlled supply-chain coordination.
Pharmaceutical and biotechnology companies evaluating Galcanezumab biological active substance commonly focus on:
Protein aggregation, charge heterogeneity, glycosylation characteristics, and target-binding activity are important quality attributes during monoclonal antibody characterization and biologic development.
Galcanezumab biological active material is primarily associated with:
Galcanezumab belongs to the class of monoclonal antibodies developed to target the CGRP pathway.
Unlike monoclonal antibodies designed to bind directly to the CGRP receptor, Galcanezumab binds to the CGRP ligand and prevents the ligand from interacting with its receptor.
Biotechnology companies evaluating Galcanezumab biological material may review:
Product-specific quality specifications should be evaluated according to the intended biologic development program, analytical strategy, reference product approach, and target regulatory market.
Galcanezumab-related biosimilar development requires extensive analytical and biological characterization.
Important comparability parameters may include:
Regulatory requirements for biosimilar development depend on the target market, proposed manufacturing process, reference product strategy, and applicable biologics guidelines.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and biotechnology customers with:
Galcanezumab biological active material is supplied in secure biologics-grade packaging selected according to protein concentration, supplied material configuration, quantity, stability requirements, and approved product specification.
Product-appropriate primary containers and protective secondary packaging are selected according to the biological material configuration.
Temperature-controlled transportation and cold-chain logistics are coordinated according to product-specific storage and shipment requirements.
Packaging configuration, MOQ, supply quantity, temperature requirements, and shipment conditions are confirmed according to the applicable product specification and customer enquiry.
Store Galcanezumab biological material under the controlled temperature conditions specified in the approved product documentation.
Protect the material from inappropriate temperature exposure, contamination, excessive agitation, and unsuitable environmental conditions.
Repeated freeze-thaw cycles should be avoided where restricted by the applicable product specification because inappropriate handling may affect protein aggregation and biological activity.
Handling should be performed by trained personnel according to approved monoclonal antibody and biological material handling procedures.
Swapnroop Drugs and Pharmaceuticals provides Galcanezumab biological active material supply and export coordination in India for qualified pharmaceutical companies, biotechnology organizations, monoclonal antibody researchers, analytical laboratories, and biologics development customers.
For Galcanezumab API price, CAS No. 1578199-75-3, protein purity, biological potency, CGRP-binding activity, COA availability, MOQ, packaging configuration, temperature requirements, and export enquiries, contact our pharmaceutical sales team.
Get Bulk Quote via WhatsApp